BiotechTube

Rocuronium + Rocuronium

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Laparoscopic Renal Surgery

Conditions

Laparoscopic Renal Surgery, Laparoscopy, Muscle Relaxation

Trial Timeline

Jul 1, 2014 → Jan 1, 2015

NCT ID
NCT02185339

About Rocuronium + Rocuronium

Rocuronium + Rocuronium is a approved stage product being developed by Merck for Laparoscopic Renal Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT02185339. Target conditions include Laparoscopic Renal Surgery, Laparoscopy, Muscle Relaxation.

What happened to similar drugs?

2 of 5 similar drugs in Laparoscopic Renal Surgery were approved

Approved (2) Terminated (1) Active (2)
🔄SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
✅Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved
✅etoricoxib 120 mgMerckApproved
🔄placebo + valdecoxib + valdecoxibPfizerPhase 3
❌N1539 + N1539 + N1539 + Ketorolac Tromethamine + PlaceboAlkermesPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02185339ApprovedCompleted

Competing Products

7 competing products in Laparoscopic Renal Surgery

See all competitors
ProductCompanyStageHype Score
Pudexacianinium chlorideAstellas PharmaPhase 2
35
SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
36
Entereg + Entereg + placeboMerckPhase 2
35
Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved
39
etoricoxib 120 mgMerckApproved
43
placebo + valdecoxib + valdecoxibPfizerPhase 3
40
N1539 + N1539 + N1539 + Ketorolac Tromethamine + PlaceboAlkermesPhase 3
29